Abstract
This review will discuss methodologies and applicability of key inflammatory models of respiratory disease in proof of concept or proof of efficacy clinical studies. In close relationship with these models, induced sputum and inflammatory cell counts will be addressed for phenotype-directed drug development. Additionally, important regulatory aspects regarding noninvestigational medicinal products used in bronchial challenges or clinical inflammatory models of respiratory disease will be highlighted.
Original language | English |
---|---|
Pages (from-to) | 37-45 |
Journal | Current Opinion in Pulmonary Medicine |
Volume | 20 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2014 |
Subject classification (UKÄ)
- Respiratory Medicine and Allergy